Agitation from Alzheimer's disease?  

Explore a Clinical Trial for Those Not Finding Relief with Current Medications.  

Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60 - 70% of cases worldwide. Over 55 million people currently live with dementia, and this number is projected to nearly double every 20 years - reaching 78 million by 2030 and 139 million by 2050. A significant symptom of AD is agitation, which affects about 50% of patients and contributes to worsened disease progression, poor quality of life, higher mortality rates, and increased institutionalization. Agitation also places a heavy burden on caregivers, increasing the risk of anxiety, depression, and the decision to institutionalize their loved ones. If you or a loved one are experiencing symptoms of agitation associated with Alzheimer’s disease you may be eligible for a clinical trial. Learn more today.  

Eligible Participants Are:

• 55 – 95 years of age
• Experiencing agitation associated with Alzheimer's disease
• 18 – 40 BMI
• Additional criteria may apply  

Eligible Participants May:

• Receive compensation for study related time and travel
• See a physician or medical staff for study related care at no cost